Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI826O)

Drug Name

BP1002 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Haematopoietic/lymphoid cancer	2B33.5	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting BCL-2 messenger RNA (BCL2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PNT-2258	DMUVON0	Diffuse large B-cell lymphoma	2A81	Phase 2	[3]
Beclanorsen	DMXVRI0	leukaemia	2A60-2B33	Phase 1/2	[4]
BP-100-1.02	DMGEYFB	Lymphoma	2A80-2A86	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04072458) A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Bio-Path Holdings.
3	Clinical pipeline report, company report or official report of ProNAi.
4	Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2844).